Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections
- PMID: 11760161
- DOI: 10.1080/00365540110027222
Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections
Abstract
The aim of this study was to determine synergistic effects of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit (ICU) infections. A total of 18 P. aeruginosa and 17 Acinetobacter strains were tested. MICs were determined using the broth microdilution method. The synergy of meropenem and ciprofloxacin was investigated in glass tubes using time-kill methodology. The synergistic effect of meropenem and ciprofloxacin in combination was found to be 22% at 0.5 x the MIC and 61% at 1 x the MIC in P. aeruginosa strains. Two strains (11%) showed synergy at both 0.5 and 1 x the MIC. Of the 18 P. aeruginosa strains, 1 strain (6%) did not show a synergistic effect at either 0.5 or 1 x the MIC. In Acinetobacter strains, the synergistic effect of meropenem and ciprofloxacin in combination was found to be 29% at 0.5 x the MIC and 18% at 1 x the MIC. One strain (6%) showed synergy at both 0.5 and 1 x the MIC. Of the 17 Acinetobacter strains, 8 strains (47%) did not show a synergistic effect at either 0.5 or 1 x the MIC. According to the results of this study, the combination of meropenem and ciprofloxacin is more effective than either antibiotic alone in ICU infections due to P. aeruginosa strains.
Similar articles
-
In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.Int J Antimicrob Agents. 2006 Mar;27(3):224-8. doi: 10.1016/j.ijantimicag.2005.10.012. Epub 2006 Feb 7. Int J Antimicrob Agents. 2006. PMID: 16464562
-
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.Antimicrob Agents Chemother. 2008 Jan;52(1):333-6. doi: 10.1128/AAC.00689-07. Epub 2007 Oct 29. Antimicrob Agents Chemother. 2008. PMID: 17967915 Free PMC article.
-
The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.Int J Antimicrob Agents. 2002 Nov;20(5):384-6. doi: 10.1016/s0924-8579(02)00192-9. Int J Antimicrob Agents. 2002. PMID: 12431875
-
Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.Antimicrob Agents Chemother. 2015 Jan;59(1):258-68. doi: 10.1128/AAC.04011-14. Epub 2014 Oct 27. Antimicrob Agents Chemother. 2015. PMID: 25348528 Free PMC article.
-
Left-sided endocarditis caused by Pseudomonas aeruginosa: successful treatment with meropenem and tobramycin.Diagn Microbiol Infect Dis. 2003 Oct;47(2):427-30. doi: 10.1016/s0732-8893(03)00135-4. Diagn Microbiol Infect Dis. 2003. PMID: 14522517 Review.
Cited by
-
Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01150-18. doi: 10.1128/AAC.01150-18. Print 2018 Nov. Antimicrob Agents Chemother. 2018. PMID: 30104278 Free PMC article.
-
Carbapenems: past, present, and future.Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60. doi: 10.1128/AAC.00296-11. Epub 2011 Aug 22. Antimicrob Agents Chemother. 2011. PMID: 21859938 Free PMC article. Review.
-
Structural changes and differentially expressed genes in Pseudomonas aeruginosa exposed to meropenem-ciprofloxacin combination.Antimicrob Agents Chemother. 2014 Jul;58(7):3957-67. doi: 10.1128/AAC.02584-13. Epub 2014 May 5. Antimicrob Agents Chemother. 2014. PMID: 24798291 Free PMC article.
-
Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant Pseudomonas aeruginosa Clinical Isolates.Antimicrob Agents Chemother. 2022 May 17;66(5):e0214021. doi: 10.1128/aac.02140-21. Epub 2022 Apr 7. Antimicrob Agents Chemother. 2022. PMID: 35389238 Free PMC article.
-
Acinetobacter baumannii: emergence of a successful pathogen.Clin Microbiol Rev. 2008 Jul;21(3):538-82. doi: 10.1128/CMR.00058-07. Clin Microbiol Rev. 2008. PMID: 18625687 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical